 REDWOOD CITY, Calif., May 26, 2022 GLOBE NEWSWIRE -- Biomea Fusion, Inc. Nasdaq: BMEA, a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced it will present new data at the American Society of Clinical Oncology ASCO Annual Meeting demonstrating BMF-219s activity in ex vivo preclinical models of CLL. In addition, the company will present a Trial In Progress TIP poster presentation detailing the design of COVALENT-101. Once released at the ASCO Annual Meeting, the preclinical and TIP presentations can be viewed on Biomeas website at . 